Emerging evidence highlights its therapeutic potential in bladder cancer (98), osteosarcoma (99), and colon cancer (100), positioning SERPINA1 as a dual prognostic biomarker and actionable target. This evidence concerns the gene SERPINA1 and urinary bladder carcinoma.